Basic Information
| RNALocate ID: | RLID:01001329 |
| RNA Symbol: | hsa-miR-24-1-5p |
| Localization: | Cytoplasm |
RNA Information
| RNA Name: | hsa-miR-189 |
| RNA ID: | miRBase:MIMAT0000079 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20498841 |
| Tissue/Cell Line: | Nasopharyngeal carcinoma cells |
| Method: | Next-generation RNA sequencing |
| Description: | The expression level of all microRNAs that detected in the nuclear and cytoplasmic 18-30nt sRNA of 293T cell line. Table S5. The N/C values of all isomiRs. The isomiRs are shown only if it displayed a raw read count (non-normalized) more than 10 in at least one library. Data are collected from Table S5, S9. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001330 | Nucleus | Nasopharyngeal carcinoma cells | 20498841 |
| RLID:11000822 | Exosome | Plasma | 23663360 |
| RLID-D:11000278 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
| RLID-D:11001157 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-24-1-5p | Oral squamous cell carcinoma | MNDR-E-MI-32377 |
| MNDR | hsa-miR-24-1-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-32378 |
| MNDR | hsa-miR-24-1-5p | Lymphoma non-hodgkin | MNDR-E-MI-32379 |
| MNDR | hsa-miR-24-1-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-32380 |
| MNDR | hsa-miR-24-1-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-32381 |
| MNDR | hsa-miR-24-1-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-32382 |
| MNDR | hsa-miR-24-1-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-32383 |
| MNDR | hsa-miR-24-1-5p | Her2-receptor positive breast cancer | MNDR-E-MI-32384 |
| MNDR | hsa-miR-24-1-5p | Breast cancer luminal | MNDR-E-MI-32385 |
| MNDR | hsa-miR-24-1-5p | Prostate cancer | MNDR-E-MI-32386 |
| MNDR | hsa-miR-24-1-5p | Chronic lymphocytic leukemia | MNDR-E-MI-32387 |
| MNDR | hsa-miR-24-1-5p | Hirschsprung disease | MNDR-E-MI-32388 |
| MNDR | hsa-miR-24-1-5p | Gastric cancer | MNDR-E-MI-32389 |
| MNDR | hsa-miR-24-1-5p | Gastric lymphoma | MNDR-E-MI-32390 |
| MNDR | hsa-miR-24-1-5p | Alzheimer disease | MNDR-E-MI-32391 |
| MNDR | hsa-miR-24-1-5p | Intracranial aneurysm | MNDR-E-MI-32392 |
| MNDR | hsa-miR-24-1-5p | Bladder cancer | MNDR-E-MI-32393 |
| MNDR | hsa-miR-24-1-5p | Esophageal carcinoma | MNDR-E-MI-32394 |
| MNDR | hsa-miR-24-1-5p | Head and neck cancer | MNDR-E-MI-32395 |
| MNDR | hsa-miR-24-1-5p | Lung cancer | MNDR-E-MI-32396 |
| MNDR | hsa-miR-24-1-5p | Parkinson disease | MNDR-E-MI-32397 |
| MNDR | hsa-miR-24-1-5p | Breast cancer | MNDR-E-MI-32398 |
| MNDR | hsa-miR-24-1-5p | Pancreatic cancer | MNDR-E-MI-32399 |
| MNDR | hsa-miR-24-1-5p | Rectum adenocarcinoma | MNDR-E-MI-32400 |
| MNDR | hsa-miR-24-1-5p | Nephroblastoma | MNDR-E-MI-32401 |
| MNDR | hsa-miR-24-1-5p | Colon cancer | MNDR-E-MI-32402 |
| MNDR | hsa-miR-24-1-5p | Colon adenocarcinoma | MNDR-E-MI-32403 |
| MNDR | hsa-miR-24-1-5p | Familial ovarian cancer | MNDR-E-MI-32404 |
| MNDR | hsa-miR-24-1-5p | Prostate adenocarcinoma | MNDR-E-MI-32405 |
| MNDR | hsa-miR-24-1-5p | Glioblastoma | MNDR-E-MI-32406 |
| MNDR | hsa-miR-24-1-5p | Astrocytoma | MNDR-E-MI-32407 |
| MNDR | hsa-miR-24-1-5p | Malignant glioma | MNDR-E-MI-32408 |
| MNDR | hsa-miR-24-1-5p | Osteosarcoma | MNDR-E-MI-32409 |
| MNDR | hsa-miR-24-1-5p | Uterine cancer | MNDR-E-MI-32410 |
| MNDR | hsa-miR-24-1-5p | Gastric adenocarcinoma | MNDR-E-MI-32411 |
| MNDR | hsa-miR-24-1-5p | Cervical squamous cell carcinoma | MNDR-E-MI-32412 |
| MNDR | hsa-miR-24-1-5p | Pituitary adenoma | MNDR-E-MI-32413 |
| MNDR | hsa-miR-24-1-5p | Lung adenocarcinoma | MNDR-E-MI-32414 |
| MNDR | hsa-miR-24-1-5p | Adrenocortical cancer | MNDR-E-MI-32415 |
| MNDR | hsa-miR-24-1-5p | Thyroid carcinoma | MNDR-E-MI-32416 |
| MNDR | hsa-miR-24-1-5p | Papillary thyroid carcinoma | MNDR-E-MI-32417 |
| MNDR | hsa-miR-24-1-5p | Bladder urothelial carcinoma | MNDR-E-MI-32418 |
| MNDR | hsa-miR-24-1-5p | Pancreatic adenocarcinoma | MNDR-E-MI-32419 |
| MNDR | hsa-miR-24-1-5p | Carcinoma renal cell | MNDR-E-MI-32420 |
| MNDR | hsa-miR-24-1-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-32421 |
| MNDR | hsa-miR-24-1-5p | Renal clear cell carcinoma | MNDR-E-MI-32422 |
| MNDR | hsa-miR-24-1-5p | Cholangiocarcinoma | MNDR-E-MI-32423 |
| MNDR | hsa-miR-24-1-5p | Esophageal cancer | MNDR-E-MI-32424 |
| MNDR | hsa-miR-24-1-5p | Hepatocellular carcinoma | MNDR-E-MI-32425 |
| MNDR | hsa-miR-24-1-5p | Familiar ovarian carcinoma | MNDR-E-MI-32426 |
| MNDR | hsa-miR-24-1-5p | B-cell lymphoma | MNDR-E-MI-32427 |
| MNDR | hsa-miR-24-1-5p | T-cell leukemia | MNDR-E-MI-32428 |
| MNDR | hsa-miR-24-1-5p | Malignant pleural mesothelioma | MNDR-E-MI-32429 |
| MNDR | hsa-miR-24-1-5p | Burkitt lymphoma | MNDR-E-MI-32430 |
| MNDR | hsa-miR-24-1-5p | Tonsil cancer | MNDR-E-MI-32431 |
| MNDR | hsa-miR-24-1-5p | Skin cutaneous melanoma | MNDR-E-MI-32432 |
| MNDR | hsa-miR-24-1-5p | Skin melanoma | MNDR-E-MI-32433 |
| MNDR | hsa-miR-24-1-5p | Colorectal cancer | MNDR-E-MI-32434 |
| MNDR | hsa-miR-24-1-5p | Nasopharynx carcinoma | MNDR-E-MI-32435 |
| MNDR | hsa-miR-24-1-5p | Multiple myeloma | MNDR-E-MI-32436 |
| MNDR | hsa-miR-24-1-5p | Ependymoma | MNDR-E-MI-32437 |
| MNDR | hsa-miR-24-1-5p | Nasopharyngeal cancer | MNDR-E-MI-32438 |
| MNDR | hsa-miR-24-1-5p | Prostatic neoplasms | MNDR-E-MI-32439 |
| MNDR | hsa-miR-24-1-5p | Stroke lacunar | MNDR-E-MI-32440 |
| MNDR | hsa-miR-24-1-5p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-32441 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | HIF1AN | Homo sapiens | RR00708042 |
TOP